Ironwood Historical Balance Sheet

IRWD Stock

USD 1.41 0.05 3.42%

Trend analysis of Ironwood Pharmaceuticals balance sheet accounts such as Other Current Liabilities of 77.7 M or Total Current Liabilities of 333.4 M provides information on Ironwood Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Ironwood Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Ironwood Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Ironwood Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ironwood Pharmaceuticals is a good buy for the upcoming year.

Ironwood Pharmaceuticals Inventory

1.21

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

About Ironwood Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Ironwood Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Ironwood Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ironwood Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ironwood currently owns. An asset can also be divided into two categories, current and non-current.

Ironwood Pharmaceuticals Balance Sheet Chart

At present, Ironwood Pharmaceuticals' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 333.4 M, whereas Total Stockholder Equity is projected to grow to (378.3 M).

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Ironwood Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ironwood Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Ironwood Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Ironwood Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Ironwood Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Ironwood Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.At present, Ironwood Pharmaceuticals' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 333.4 M, whereas Total Stockholder Equity is projected to grow to (378.3 M).

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	415.9M	715.5M	822.9M	864.0M
Total Assets	1.1B	471.1M	541.7M	499.5M

Short Long Term Debt Total Total Assets

Ironwood Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.45	0.21	0.12	0.63	0.04	-0.19	0.15	-0.12	-0.19	-0.2	0.83	0.85	0.25	0.9	0.51	0.85	0.55	0.56	0.77	0.49	0.3	0.64	0.37	-0.2	0.94
Short Long Term Debt Total	0.45		0.8	0.81	-0.38	-0.19	-0.36	-0.31	0.79	-0.81	-0.23	0.21	0.54	0.0	0.09	0.97	-0.01	0.93	0.63	0.7	0.76	0.79	0.71	0.96	-0.18	0.31
Other Current Liab	0.21	0.8		0.87	-0.42	-0.45	-0.21	-0.02	0.69	-0.48	-0.59	0.1	0.35	-0.39	-0.1	0.66	-0.2	0.76	0.3	0.33	0.4	0.61	0.35	0.75	0.01	0.09
Total Current Liabilities	0.12	0.81	0.87		-0.55	-0.27	-0.31	-0.2	0.81	-0.54	-0.2	-0.09	0.36	-0.29	-0.19	0.64	-0.33	0.64	0.3	0.26	0.4	0.63	0.31	0.81	-0.08	-0.06
Total Stockholder Equity	0.63	-0.38	-0.42	-0.55		0.0	0.3	0.44	-0.82	0.47	-0.09	0.74	0.32	0.1	0.82	-0.29	0.89	-0.21	0.13	0.25	-0.27	-0.25	0.1	-0.49	0.13	0.73
Other Liab	0.04	-0.19	-0.45	-0.27	0.0		-0.24	-0.16	0.03	0.01	0.67	-0.34	0.24	0.9	0.09	-0.06	0.0	-0.25	-0.07	-0.11	0.28	-0.32	-0.06	0.03	-0.34	-0.1
Property Plant And Equipment Net	-0.19	-0.36	-0.21	-0.31	0.3	-0.24		0.14	-0.3	0.16	0.06	-0.05	-0.33	-0.16	-0.13	-0.35	0.04	-0.43	0.21	-0.1	-0.6	-0.01	-0.01	-0.55	0.94	-0.07
Current Deferred Revenue	0.15	-0.31	-0.02	-0.2	0.44	-0.16	0.14		-0.49	0.38	-0.42	0.33	-0.02	-0.15	0.3	-0.36	0.34	-0.18	-0.17	-0.19	-0.34	-0.32	-0.15	-0.35	0.05	0.24
Net Debt	-0.12	0.79	0.69	0.81	-0.82	0.03	-0.3	-0.49		-0.76	0.04	-0.43	0.18	0.04	-0.46	0.72	-0.57	0.59	0.34	0.24	0.58	0.6	0.35	0.84	-0.09	-0.3
Retained Earnings	-0.19	-0.81	-0.48	-0.54	0.47	0.01	0.16	0.38	-0.76		-0.11	0.04	-0.28	-0.26	0.1	-0.86	0.16	-0.74	-0.74	-0.68	-0.74	-0.76	-0.81	-0.76	0.01	-0.09
Accounts Payable	-0.2	-0.23	-0.59	-0.2	-0.09	0.67	0.06	-0.42	0.04	-0.11		-0.41	-0.04	0.59	-0.11	-0.13	-0.16	-0.39	0.1	-0.09	0.0	-0.06	0.01	-0.12	-0.02	-0.27
Cash	0.83	0.21	0.1	-0.09	0.74	-0.34	-0.05	0.33	-0.43	0.04	-0.41		0.47	-0.1	0.84	0.26	0.88	0.42	0.34	0.61	0.14	0.22	0.43	0.06	-0.13	0.93
Non Current Assets Total	0.85	0.54	0.35	0.36	0.32	0.24	-0.33	-0.02	0.18	-0.28	-0.04	0.47		0.33	0.71	0.56	0.5	0.56	0.53	0.66	0.62	0.26	0.59	0.55	-0.23	0.62
Non Currrent Assets Other	0.25	0.0	-0.39	-0.29	0.1	0.9	-0.16	-0.15	0.04	-0.26	0.59	-0.1	0.33		0.27	0.19	0.21	-0.01	0.25	0.22	0.46	-0.09	0.3	0.14	-0.27	0.16
Other Assets	0.9	0.09	-0.1	-0.19	0.82	0.09	-0.13	0.3	-0.46	0.1	-0.11	0.84	0.71	0.27		0.17	0.9	0.26	0.33	0.56	0.23	0.05	0.41	0.03	-0.23	0.88
Long Term Debt	0.51	0.97	0.66	0.64	-0.29	-0.06	-0.35	-0.36	0.72	-0.86	-0.13	0.26	0.56	0.19	0.17		0.1	0.92	0.71	0.8	0.85	0.76	0.8	0.92	-0.21	0.4
Cash And Short Term Investments	0.85	-0.01	-0.2	-0.33	0.89	0.0	0.04	0.34	-0.57	0.16	-0.16	0.88	0.5	0.21	0.9	0.1		0.14	0.35	0.55	0.12	-0.01	0.4	-0.11	-0.08	0.94
Net Receivables	0.55	0.93	0.76	0.64	-0.21	-0.25	-0.43	-0.18	0.59	-0.74	-0.39	0.42	0.56	-0.01	0.26	0.92	0.14		0.58	0.76	0.77	0.75	0.73	0.87	-0.29	0.46
Common Stock Total Equity	0.56	0.63	0.3	0.3	0.13	-0.07	0.21	-0.17	0.34	-0.74	0.1	0.34	0.53	0.25	0.33	0.71	0.35	0.58		0.89	0.54	0.62	0.96	0.46	0.31	0.5
Common Stock Shares Outstanding	0.77	0.7	0.33	0.26	0.25	-0.11	-0.1	-0.19	0.24	-0.68	-0.09	0.61	0.66	0.22	0.56	0.8	0.55	0.76	0.89		0.69	0.63	0.94	0.56	-0.02	0.72
Non Current Liabilities Total	0.49	0.76	0.4	0.4	-0.27	0.28	-0.6	-0.34	0.58	-0.74	0.0	0.14	0.62	0.46	0.23	0.85	0.12	0.77	0.54	0.69		0.4	0.7	0.83	-0.47	0.32
Other Current Assets	0.3	0.79	0.61	0.63	-0.25	-0.32	-0.01	-0.32	0.6	-0.76	-0.06	0.22	0.26	-0.09	0.05	0.76	-0.01	0.75	0.62	0.63	0.4		0.66	0.67	0.07	0.27
Other Stockholder Equity	0.64	0.71	0.35	0.31	0.1	-0.06	-0.01	-0.15	0.35	-0.81	0.01	0.43	0.59	0.3	0.41	0.8	0.4	0.73	0.96	0.94	0.7	0.66		0.58	0.08	0.57
Total Liab	0.37	0.96	0.75	0.81	-0.49	0.03	-0.55	-0.35	0.84	-0.76	-0.12	0.06	0.55	0.14	0.03	0.92	-0.11	0.87	0.46	0.56	0.83	0.67	0.58		-0.38	0.19
Property Plant And Equipment Gross	-0.2	-0.18	0.01	-0.08	0.13	-0.34	0.94	0.05	-0.09	0.01	-0.02	-0.13	-0.23	-0.27	-0.23	-0.21	-0.08	-0.29	0.31	-0.02	-0.47	0.07	0.08	-0.38		-0.15
Total Current Assets	0.94	0.31	0.09	-0.06	0.73	-0.1	-0.07	0.24	-0.3	-0.09	-0.27	0.93	0.62	0.16	0.88	0.4	0.94	0.46	0.5	0.72	0.32	0.27	0.57	0.19	-0.15

Click cells to compare fundamentals

Ironwood Pharmaceuticals Account Relationship Matchups

Ironwood Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	559.2M	1.1B	1.1B	471.1M	541.7M	499.5M
Short Long Term Debt Total	453.7M	475.8M	415.9M	715.5M	822.9M	864.0M
Other Current Liab	25.3M	40.6M	18.3M	64.3M	74.0M	77.7M
Total Current Liabilities	32.7M	161.7M	25.5M	276.1M	317.5M	333.4M
Total Stockholder Equity	62.6M	605.9M	652.4M	(346.3M)	(398.2M)	(378.3M)
Other Liab	25.0M	13.3M	3.5M	9.8M	8.8M	8.3M
Property Plant And Equipment Net	25.5M	22.9M	20.3M	18.2M	16.4M	19.6M
Current Deferred Revenue	875K	28.4M	39.5M	1.2M	1.1M	1.1M
Net Debt	91.1M	(144.3M)	(240.3M)	623.4M	716.9M	752.7M
Retained Earnings	(1.5B)	(937.6M)	(696.4M)	(1.7B)	(1.5B)	(1.5B)
Accounts Payable	661K	935K	483K	7.8M	9.0M	8.6M
Cash	362.6M	620.1M	656.2M	92.2M	106.0M	206.6M
Non Current Assets Total	63.4M	381.7M	319.9M	237.8M	273.5M	143.0M
Non Currrent Assets Other	37.1M	25.5M	15.9M	3.6M	4.1M	3.9M
Other Assets	54.5M	358.8M	299.6M	1.0	1.15	1.09
Long Term Debt	430.3M	337.3M	396.3M	498.3M	573.1M	601.7M
Cash And Short Term Investments	362.6M	620.1M	656.2M	92.2M	106.0M	100.7M
Net Receivables	122.4M	114.0M	115.5M	129.1M	148.5M	155.9M
Common Stock Total Equity	154K	158K	161K	162K	177.1K	125.3K
Common Stock Shares Outstanding	160.7M	164.4M	186.3M	155.4M	160.2M	139.3M
Liabilities And Stockholders Equity	559.2M	1.1B	1.1B	471.1M	541.7M	499.5M
Non Current Liabilities Total	463.9M	359.3M	422.6M	541.3M	622.5M	370.6M
Other Current Assets	10.9M	11.1M	9.0M	12.0M	10.8M	17.8M
Other Stockholder Equity	1.5B	1.5B	1.3B	1.4B	1.6B	1.0B
Total Liab	496.6M	521.0M	448.1M	817.4M	940.0M	987.0M
Property Plant And Equipment Gross	25.5M	22.9M	20.3M	27.1M	24.4M	20.1M
Total Current Assets	495.8M	745.2M	780.6M	233.3M	268.3M	356.5M
Accumulated Other Comprehensive Income	(65.2M)	0.0	(11.8M)	(3.0M)	(3.5M)	(3.7M)
Short Term Debt	6.3M	120.0M	6.1M	202.7M	233.1M	244.7M
Common Stock	158K	161K	162K	156K	179.4K	128.1K
Property Plant Equipment	12.4M	8.9M	22.9M	6.3M	5.7M	5.4M
Net Tangible Assets	(72.0M)	83.0M	605.9M	669.0M	769.3M	807.8M
Retained Earnings Total Equity	(1.6B)	(1.5B)	(937.6M)	(696.4M)	(626.7M)	(658.1M)
Long Term Debt Total	408.0M	430.3M	337.3M	396.3M	455.7M	311.5M
Capital Surpluse	1.5B	1.5B	1.5B	1.3B	1.6B	1.3B
Capital Lease Obligations	23.4M	21.6M	19.7M	17.7M	20.3M	21.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:

How To Invest In Ironwood

Details

Is Ironwood Stock a good investment?

Details

What is Ironwood Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.77)

Earnings Share

0.01

Revenue Per Share

1.938

Quarterly Revenue Growth

(0.23)

Return On Assets

0.1481

The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ironwood Historical Balance Sheet

Ironwood Pharmaceuticals Inventory

1.21

About Ironwood Balance Sheet Analysis

Ironwood Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Ironwood Pharmaceuticals balance sheet Correlations

Ironwood Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ironwood Pharmaceuticals balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Long Term Debt	+ 0.97	Short Long Term Debt Total
Total Liab	+ 0.96	Short Long Term Debt Total
Other Stockholder Equity	+ 0.96	Common Stock Total Equity
Total Current Assets	+ 0.94	Total Assets
Property Plant And Equipment Gross	+ 0.94	Property Plant And Equipment Net
Total Current Assets	+ 0.94	Cash And Short Term Investments

Long Term Debt	- 0.86	Retained Earnings
Net Debt	- 0.82	Total Stockholder Equity
Other Stockholder Equity	- 0.81	Retained Earnings
Retained Earnings	- 0.81	Short Long Term Debt Total
Total Liab	- 0.76	Retained Earnings
Other Current Assets	- 0.76	Retained Earnings